Merck delivers vital data on evobrutinib
Treatment is an BTK inhibitor and has demonstrated a sound safety and tolerability profile
Read More
Tag: Merck
Scottish Medicines Consortium recommends Merck’s Tepmetko
Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients
Read More
MSD’s pembrolizumab therapy gets NICE approval
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning
Read More
Cerevance establishes strategic research collaboration with Merck
Partnership will focus on the discovery of novel targets in Alzheimer’s disease
Read More
Merck and Mulliken Center collaborate for machine learning project
The three-year project will focus on molecular representations and computational tools
Read More
NICE approves Merck’s Keytruda for adult patients with rare triple negative breast cancer
The injection is given in combination with chemotherapy and administered once every three weeks
Read More
NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio
Following successful appeals, the therapy has been recommended for all eligible bladder cancer patients
Read More
SMC approves Bavencio for bladder cancer
The treatment was not recommended by NICE for the NHS in England
Read More
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA
The positive opinion has been issued via the MHRA’s early access the medicine (EAMS) scheme
Read More
Merck partners with Innervia on bioelectronic therapy development
Collaboration will focus on the development of smart neurostimulators for the treatment of severe chronic diseases
Read More
Merck extends oncology and autoimmunity collaboration with BioMed X
Merck will launch an additional six research projects at the BioMed X Institute on top of its ongoing research projects
Read More
Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Read More
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
- Oregon and Lantern collaborate to develop drug candidate for various cancer indications
- OneChain’s CAR T trial treats its first cortical T-cell ALL patient
- Johns Hopkins scientists depict molecular pathway to track replication in cancer cells
